AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 123 min read$CRVS

Corvus Pharmaceuticals, Inc. (CRVS): Submission of Matters to a Vote of Security Holders

Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001626971 0001626971 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Original reporting
SEC EDGAR 8-K
Published Jun 12, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$CRVS
Neutral
medium confidence
Mentioned
$CRVS
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CRVSNeutralLow
01

Why it matters

Vote results confirm: (1) Class I director elections, (2) ratification of PricewaterhouseCoopers LLP as independent auditor for FY ending Dec. 31, 2026, and (3) a non-binding advisory approval of named executive officer compensation.

02

Market read

Primarily governance/oversight confirmation; no new clinical, financial, or regulatory catalyst is disclosed.

03

What to watch

Traders may overreact to vote tallies; without accompanying changes (CEO/CFO/board turnover, financing, or regulatory updates), the practical trading edge is limited.

Relevance 6/10Novelty 3/10Timing: Filed June 12, 2026 for the June 11, 2026 annual meeting vote results

Background

The company submitted the formal results of its June 11, 2026 annual stockholder meeting on SEC Form 8-K (Item 5.07).

Company-level read

Ticker impact

$CRVSNeutralMedium confidence
Context

Corvus Pharmaceuticals filed an 8-K reporting the results of its 2026 annual stockholder vote, including director elections and auditor ratification.

Expected impact

Likely low/short-lived impact; any reaction would be sentiment-driven rather than driven by new financial or regulatory information.

Evidence & confidence

The filing discloses vote tallies for three proposals but does not introduce new guidance, trial data, financing, or enforcement/regulatory outcomes.

Market effects

Sector

Minimal; governance vote results are not sector-level catalysts.

Regional

Minimal; no regional macro or policy linkage.

Global

Minimal; no international transaction or regulatory action disclosed.

Counterpoint

What could challenge this read

If vote outcomes signal shareholder dissatisfaction (e.g., elevated withheld votes or compensation opposition), it could modestly raise perceived governance risk, but the filing provides no narrative or follow-on actions.

Key entities

  • issuer
    Corvus Pharmaceuticals, Inc.

    Nasdaq-listed company whose annual meeting vote results were reported on Form 8-K.

  • auditor
    PricewaterhouseCoopers LLP

    Independent registered public accounting firm ratified by stockholders for FY ending Dec. 31, 2026.

  • director_nominee
    Richard A. Miller, M.D.

    Class III director nominee elected (Class I director nominee per filing section).

  • director_nominee
    Linda S. Grais, M.D., J.D.

    Class III director nominee elected (Class I director nominee per filing section).

Read at source← All news

Related articles

AUG 7
$CRVSMed

Corvus Pharmaceuticals Q2 Earnings Call Highlights

Corvus Pharmaceuticals (NASDAQ:CRVS) said an interim futility analysis for its PTCL Phase III trial is expected in Q1 2027, with an independent committee deciding whether to continue. Final Phase III PTCL data are still expected in late 2027. For atopic dermatitis, soquelitinib Phase I results showed EASI-75 of 75% vs 20% placebo; SIERRA-1 enrollment ends early 2027 with top-line data in Q3 2027.

yahoo.com6 min
AUG 6
$CRVSMed

Corvus Pharmaceuticals, Inc. (CRVS): Results of Operations and Financial Condition

Corvus Pharmaceuticals, Inc. (CRVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopi

SEC EDGAR 8-K5 min
AUG 9
$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

rttnews.com2 min
AUG 9
$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

rte.ie6 min
AUG 9
$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.

yahoo.com6 min